CORRECTING and REPLACING US FDA Action Enables Millions of American Smokers to Give Up Cigarettes
Second paragraph, second sentence of release should read: PMI will bring IQOS to the U.S. in cooperation with Altria Group, Inc., and its subsidiary Philip Morris USA (instead of PMI will bring IQOS to the U.S. in cooperation with Altria Companies, Inc., and its subsidiary Philip Morris USA).
The corrected release reads:
US FDA ACTION ENABLES MILLIONS OF AMERICAN SMOKERS TO GIVE UP CIGARETTES
Philip Morris International and Altria Will Make Better Choices Available Through Socially Responsible Practices
On April 30, the United States Food and Drug Administration (FDA) issued a marketing order authorizing IQOS, Philip Morris International’s (PMI) electrically heated tobacco system, for sale in the United States, confirming that it is appropriate for the protection of public health. This is a historic milestone both in the agency’s history and for American men and women who smoke, nine out of 10 of whom would otherwise continue to smoke.
Acting under a 2009 statute, the FDA carefully and objectively assessed an enormous amount of scientific data and deployed its regulatory authority to make a better choice available to millions of Americans who currently smoke cigarettes. PMI will bring IQOS to the U.S. in cooperation with Altria Group, Inc., and its subsidiary Philip Morris USA.
“For too long, there has been an ideological battle over tobacco products in the U.S., with cigarette companies at the center of a heated debate. In our view, and the view of many long-standing tobacco control advocates, it’s time to put the tobacco wars aside and instead focus on what’s best for the millions of men and women who smoke in the U.S.,” said Dr. Moira Gilchrist, PMI’s VP Strategic and Scientific Communications. “It’s time to treat them like adults and—under the FDA’s careful oversight—enable them to leave cigarettes behind forever, including by switching to scientifically substantiated better alternatives such as the one the FDA has now authorized.”
In bringing IQOS to market in the U.S., PMI will comply with existing federal and state laws that apply to tobacco products and will likewise follow the additional specific requirements in FDA’s marketing order to minimize any unintended use by never smokers, especially youth.
Shortly after receiving the order, PMI and Altria received a letter from Matthew Myers, president of the Campaign for Tobacco-Free Kids (CTFK). One of Mr. Myer’s main objectives for many years has been to achieve U.S. FDA oversight of tobacco products, including so that tobacco companies be required “to make technologically feasible changes to tobacco products to reduce the number and quantity of harmful substances in those products.” That ambition is now a reality.
CTFK’s letter requested assurances from PMI in relation to the launch of IQOS in the U.S. PMI has adopted a business strategy that aims to replace cigarettes with innovative, smoke-free alternatives. For those who continue smoking, our goal is to maximize adult smoker awareness of and access to alternatives like IQOS, while minimizing use by nonsmokers (and that of youth, in particular). In our reply to CTFK, Dr. Gilchrist emphasized our simple message: “If you don’t smoke, don’t start; if you smoke, quit; if you don’t quit, change. Just as CTFK aims to prevent youth tobacco and nicotine use—which we wholeheartedly support—we also aim for smoke-free adults, a companion goal that we hope CTFK would also support.”
For a complete copy of Dr. Gilchrist’s reply, please click here.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2019, PMI estimates that approximately 7.3 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, which is currently available for sale in 47 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.
Philip Morris International Media Office
T. +1 (202) 679 7296
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
GLIDE and eBay Present the 20th Annual Auction for Power Lunch with Warren Buffett, May 26 – May 3120.5.2019 11:00:00 CEST | Pressemelding
GLIDE is pleased to announce the annual eBay for Charity Auction for Power Lunch with Warren Buffett, which will begin at 7:30 pm PDT on Sunday, May 26 and end at 7:30 pm PDT on Friday, May 31, 2019. This year marks the 20th anniversary of the legendary auction, which to date has provided nearly $30 million to support GLIDE’s comprehensive suite of social services that help San Francisco’s most vulnerable residents overcome hunger, poverty, homelessness and health challenges as well as social isolation and marginalization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005017/en/ “It makes a difference, and it translates into human beings finding that there is hope in life and that something better is there,” Mr. Buffett said recently about the money raised for GLIDE over the past 20 years. The annual Power Lunch with Warren Buffett is made possible through the support of eBay for Charity. The winning bidder and up to
PEI-Genesis Promotes Peter Austin to General Manager North America and Corporate Senior Vice President20.5.2019 11:00:00 CEST | Pressemelding
PEI-Genesis, the world’s fastest assembler of precision connectors, has promoted Peter Austin to General Manager North America and Corporate Senior Vice President, effective immediately. He will continue to report directly to Steven Fisher, PEI-Genesis Chairman and CEO. “Since joining PEI-Genesis in 2016, Peter has proven to be a valuable leader and an unparalleled strategic thinker in working to move the business forward,” said Fisher. “With his decades of experience in the electronics industry, his innovative thinking, and his ability to lead teams across North America, we have many accomplishments to tout, all directly related to his work.” In addition to his current responsibilities, in his new General Manager role, Austin will have responsibility for all operations in North America, including the company’s production facilities in South Bend, IN, Chandler, AZ, and Nogales, Mexico. He’ll also have leadership of the company’s North American Sales units. “My tenure at PEI has been a
Enlighted Expands IoT Platform Lighting Control Capabilities20.5.2019 10:00:00 CEST | Pressemelding
Enlighted, the leading provider of Internet of Things (IoT) solutions for commercial buildings and healthcare facilities, today announced new lighting control capabilities have been added to its award-winning building IoT Platform. These include advanced tunable white lighting control, daylight harvesting group capabilities, and a two-wire interface for the company’s powerful sensors. Together these new advancements improve the health and well-being of building occupants, improve lighting aesthetics, simplify fixture integration and reduce costs. Advanced Tunable White Lighting Control Enlighted sensors go beyond the automated circadian rhythm capabilities typically found in today’s tunable white solutions and now provide user-level control of color temperature to desired levels. The color temperature can be automatically aligned with the astronomical clock or directly tuned according to specific user needs. Occupants can tailor their environment, improve productivity and comfort, and
ams, Ibeo and ZF Partner to Deliver Industry-First Solid-State LiDAR Systems for the Automotive Industry20.5.2019 09:36:00 CEST | Pressemelding
ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, announces today that it has signed an agreement to team with Ibeo Automotive Systems GmbH, the German specialist for automotive LiDAR sensor technology, and ZF Friedrichshafen AG, one of the leading technology companies for mobility worldwide to advance solid-state LiDAR technology for use in autonomous driving and other applications. The three companies will partner on joint R&D efforts to ensure that this exciting technology can be quickly and safely adopted by 2021. LiDAR is an optical sensing technology that measures distance and direction of the surrounding objects by illuminating them with a laser beam and detecting the reflection of the object. Its unique range and resolution properties complement radar and camera solutions to enable the ‘Holy Grail’ of the self-driving car industry – SAE level 5* or fully autonomous driving. ams will provide automotive-grade VCSEL (Vertical Cavity Surface Emittin
Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 201920.5.2019 07:05:00 CEST | Pressemelding
Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST. The presentation, entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy. ImmunoID NeXT™ is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery20.5.2019 07:00:00 CEST | Pressemelding
Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005244/en/ Masimo Radical-7® with SpHb® (Photo: Business Wire) Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enroll